Isopathic versus enantiomeric inhibition of U-50488 HCl toxicity--experimental studies.
BACKGROUND
Previous studies have investigated toxicity inhibition of optically active compounds by potentized preparations of their enantiomers. It was hypothesised that inhibition of toxicity may be stereospecific. This paper presents 2 studies investigating stereoisomer potencies in terms of their ability to counteract toxicity of the (-) stereoisomer. The stereoisomers used were (-)-trans-(1S,2S)-U-50488 HCl and (+)-trans-(1R,2R)-U-50488 HCl.


METHODS
Designs were prospective, blind, randomised, intention-to-treat and compared the efficacy of 2 indistinguishable treatments. The outcome was the difference in survival. Potency 'chords' consisting of 4th, 12th and 30th approximately centesimal dilutions were prepared, representing concentrations of 1.08 x 10(-10) M. One study compared inhibition of (-)-U-50488 toxicity injected ip at the estimated LD50 into male ICR mice, treated with a potency chord of the same stereoisomer, with control ('isopathic' study). The other study compared inhibition of toxicity by potency chords made from the stereoisomers (+)-U-50488 and (-)-U-50488 ('enantiomer' study), Treatments were administered orally on 11 occasions: twice before and nine times after ip injections.


RESULTS
The isopathic study did not yield a significant result. In the enantiomer study, comparison of isopathy with enantiomer potency treatment showed a highly significant difference odds ratio 1.97 (95% CI: 1.23-3.14).


CONCLUSIONS
We conclude that enantiomeric potencies are superior to identically produced isopathic potencies, in inhibiting toxicity of (-)-U-50488 HCl. Homeopathic inhibition of toxicity may be stereospecific.
Kuzeff
R M
RM
National Institute of Integrative Medicine, Melbourne, Australia. kuzeffm@ausdoctors.net
Topashka-Ancheva
M
M
Metcheva
R
R
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / Q000633:toxicity*; D018712:Analgesics, Non-Narcotic / Q000633:toxicity*; D000818:Animals; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011446:Prospective Studies; D011897:Random Allocation; D013237:Stereoisomerism
D018712:Analgesics, Non-Narcotic; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer